{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-24-000033","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2024-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.272653+00:00","generated_at":"2026-06-06T07:35:26.566847+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neurocrine Q4 INGREZZA sales $500M (+25% YoY); FY 2024 guidance $2.1-$2.2B","bullets":["Q4 GAAP net income $147.7M ($1.44 diluted EPS) vs $89M ($0.88) in Q4 2022; non-GAAP EPS $1.54.","Full-year 2023 INGREZZA net product sales $1.84B (+29% YoY); total revenue $1.89B.","FY 2024 INGREZZA sales guidance $2.1–$2.2B; GAAP R&D $645–$675M, SG&A $930–$950M.","Patent litigation resolved; generic INGREZZA entry no earlier than March 2038.","Crinecerfont FDA submission for congenital adrenal hyperplasia expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-24-000033","json":"https://secwatch.observer/filing/0000914475-24-000033.json","markdown":"https://secwatch.observer/filing/0000914475-24-000033.md","text":"https://secwatch.observer/filing/0000914475-24-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000033/0000914475-24-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000033/nbix-20240207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T07:35:26.566847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"79beccdada401352fa3ddd164308ebcfff172322","claim":"NEUROCRINE BIOSCIENCES INC updated its the fourth quarter and fiscal year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On February 7, 2024, Neurocrine Biosciences, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000033/0000914475-24-000033-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}